BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 2,709 shares of the stock in a transaction dated Monday, April 19th. The stock was sold at an average price of $79.58, for a total value of $215,582.22. Following the transaction, the executive vice president now owns 71,149 shares of the company’s stock, valued at approximately $5,662,037.42. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of BMRN stock opened at $79.70 on Friday. The firm has a 50 day moving average price of $77.45 and a two-hundred day moving average price of $80.56. The company has a quick ratio of 2.38, a current ratio of 3.20 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $14.49 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 3.89 and a beta of 0.71. BioMarin Pharmaceutical Inc. has a 12-month low of $71.35 and a 12-month high of $131.95.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, February 25th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.18. The firm had revenue of $452.12 million during the quarter, compared to the consensus estimate of $447.17 million. BioMarin Pharmaceutical had a net margin of 45.74% and a return on equity of 4.34%. As a group, research analysts expect that BioMarin Pharmaceutical Inc. will post 0.6 EPS for the current year.
A number of research firms have issued reports on BMRN. Evercore ISI upgraded BioMarin Pharmaceutical from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $90.00 to $100.00 in a report on Monday, March 8th. Robert W. Baird restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Monday, March 1st. Morgan Stanley reduced their price objective on shares of BioMarin Pharmaceutical from $85.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday. Wedbush restated an “outperform” rating and set a $139.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, March 23rd. Finally, Canaccord Genuity reduced their price objective on shares of BioMarin Pharmaceutical from $95.00 to $91.00 and set a “buy” rating for the company in a research note on Monday, March 8th. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $117.74.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Article: What is the Producer Price Index (PPI)?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.